Adverse effects of GLP-1 receptor agonists: difference between revisions
Diff·revision 8 → 9·10:23, 5 Sep 2024
Difference between revision 8 and revision 9 of Adverse effects of GLP-1 receptor agonists. 3 lines changed; the page grew by 523 bytes.
| Revision 8 — 15:16, 27 Aug 2024 LeanMassLars (talk) rm the reassurance sentence; the article should report, not reassure 2,614 bytes +31 | Revision 9 — 10:23, 5 Sep 2024 RegainRomilly (talk) rm the causal wording — spontaneous reports do not establish causation 3,137 bytes +523 | ||
|---|---|---|---|
| 24 | Attenuation over time parallels the attenuation of the gastric-emptying delay, and is the reason escalation schedules work: adaptation to the gastrointestinal effect occurs while the appetite and glycaemic effects persist. See [[Dose escalation schedule]].{{r|drucker2018}} | 24 | Attenuation over time parallels the attenuation of the gastric-emptying delay, and is the reason escalation schedules work: adaptation to the gastrointestinal effect occurs while the appetite and glycaemic effects persist. See [[Dose escalation schedule]].{{r|drucker2018}} |
| 25 | 25 | ||
| + | 26 | Discontinuation for adverse events ran at about 7% in [[STEP trial programme|STEP 1]] and 16.6% in [[SELECT trial|SELECT]], where treatment continued for over three years. Longer exposure produces more cumulative discontinuation even where per-period tolerability is similar.{{r|lincoff2023}} | |
| + | 27 | ||
| 26 | == References == | 28 | == References == |
| 27 | {{reflist}} | 29 | {{reflist}} |
| 28 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 30 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| 29 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> | 31 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> |
| + | 32 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> | |
| 30 | 33 | ||
| 31 | {{DEFAULTSORT:Adverse effects of GLP-1 receptor agonists}} | 34 | {{DEFAULTSORT:Adverse effects of GLP-1 receptor agonists}} |